FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrea Foli

Research Profile

Chemicals & Drugs

Disorders

Living Beings

HIV-1

Procedures

Concepts & Ideas

Physiology

Anatomy

Co-author Network

Publications

TOP 3
Giovanni Palladini; Stefano Perlini; Paola Russo; Andrea Foli; Francesca Lavatelli; Paolo Milani; Mario Nuvolone; Giampaolo Merlini
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Giovanni Palladini; Stefano Perlini; Paola Russo; Paolo Milani; Remigio Moratti; Laura Obici; Riccardo Albertini; Andrea Foli; Francesca Lavatelli; Giampaolo Merlini
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Riccardo Caccialanza; Barbara Cameletti; Emanuele Cereda; Andrea Foli; Catherine Klersy; Francesca Lavatelli; Paolo Milani; Elisabetta Montagna; Giovanni Palladini; Paola Russo; Chiara Bonardi; Giampaolo Merlini
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrea Foli (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Giovanni Palladini; Stefano Perlini; Paola Russo; Andrea Foli; Francesca Lavatelli; Paolo Milani; Mario Nuvolone; Giampaolo Merlini
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Haematologica 2013;98(3):433-6.
2012: Giovanni Palladini; Stefano Perlini; Paola Russo; Paolo Milani; Remigio Moratti; Laura Obici; Riccardo Albertini; Andrea Foli; Francesca Lavatelli; Giampaolo Merlini
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
American journal of hematology 2012;87(5):465-71.
2012: Riccardo Caccialanza; Barbara Cameletti; Emanuele Cereda; Andrea Foli; Catherine Klersy; Francesca Lavatelli; Paolo Milani; Elisabetta Montagna; Giovanni Palladini; Paola Russo; Chiara Bonardi; Giampaolo Merlini
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.
Annals of hematology 2012;91(3):399-406.
2011: Giovanni Palladini; Stefano Perlini; Paola Russo; Gabriele Sarais; Riccardo Albertini; Alessandra Barassi; Simona Casarini; Andrea Foli; Francesca Lavatelli; Gian Vico Melzi d'Eril; Paolo Milani; Remigio Moratti; Laura Obici; Giampaolo Merlini
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2011;18(4):216-21.
2011: Giovanni Palladini; Andrea Foli; Paola Russo; Paolo Milani; Laura Obici; Francesca Lavatelli; Giampaolo Merlini
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Clinical lymphoma, myeloma & leukemia 2011;11(1):143-5.
2010: Giovanni Palladini; Alessandra Barassi; Catherine Klersy; Rosana Pacciolla; Paolo Milani; Gabriele Sarais; Stefano Perlini; Riccardo Albertini; Paola Russo; Andrea Foli; Letizia Zenone Bragotti; Laura Obici; Remigio Moratti; Gian Vico Melzi d'Eril; Giampaolo Merlini
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Blood 2010;116(18):3426-30.
2009: Stefania Paolucci; Andrea Foli; Roberto Gulminetti; Sandra A Calarota; Renato Maserati; Fausto Baldanti; Giuseppe Gerna
HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response.
Current HIV research 2009;7(3):302-10.
2009: Giovanni Palladini; Paola Russo; Tiziana Bosoni; Gabriele Sarais; Francesca Lavatelli; Andrea Foli; Letizia Zenone Bragotti; Vittorio Perfetti; Laura Obici; Franco Bergesio; Riccardo Albertini; Remigio Moratti; Giampaolo Merlini
AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
Clinical lymphoma & myeloma 2009;9(1):80-3.
2008: Sandra A Calarota; Andrea Foli; Renato Maserati; Fausto Baldanti; Stefania Paolucci; Mary A Young; Christos M Tsoukas; Julianna Lisziewicz; Franco Lori
HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):5907-15.
2008: Brett D Shepard; Davide De Forni; David R McNamara; Andrea Foli; Stacey A Rizza; Roshini S Abraham; Keith Knutson; Peter J Wettstein; Franco Lori; andrew badley
Beneficial effect of TRAIL on HIV burden, without detectable immune consequences.
PloS one 2008;3(8):e3096.
2007: Andrea Foli; Maria Angela Maiocchi; Julianna Lisziewicz; Franco Lori
A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication.
The Journal of infectious diseases 2007;196(9):1409-15.
2007: Renato Maserati; Andrea Foli; Lina Tomasoni; Laura Sighinolfi; Franco Maggiolo; Daria Sacchini; Massimo Di Pietro; Davide Bertelli; Carmine Tinelli; Franco Lori
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.
Current HIV research 2007;5(3):337-43.
2007: Franco Lori; Andrea Foli; Julianna Lisziewicz
Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options.
Current opinion in HIV and AIDS 2007;2(1):14-20.
2007: Franco Lori; Andrea Foli; Laurene M Kelly; Julianna Lisziewicz
Virostatics: a new class of anti-HIV drugs.
Current medicinal chemistry 2007;14(2):233-41.
2005: Franco Lori; Andrea Foli; Antonella Groff; Luca Lova; Lucia Whitman; Nyasha Bakare; Richard B Pollard; Julianna Lisziewicz
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
AIDS (London, England) 2005;19(11):1173-81.
2005: Franco Lori; Richard B Pollard; Lucia Whitman; Nyasha Bakare; G Blick; P Shalit; Andrea Foli; D Peterson; A Tennenberg; S Schrader; B Rashbaum; C Farthing; D Herman; D Norris; P Greiger; I Frank; Antonella Groff; Luca Lova; David M Asmuth; Julianna Lisziewicz
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
AIDS research and human retroviruses 2005;21(4):263-72.
2005: Luca Lova; Antonella Groff; Elisabetta Ravot; Giuditta Comolli; Jianqing Xu; Lucia Whitman; Mark Lewis; Andrea Foli; Julianna Lisziewicz; Franco Lori
Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes.
AIDS (London, England) 2005;19(2):137-44.
2004: Franco Lori; Laurene M Kelly; Andrea Foli; Julianna Lisziewicz
Safety of hydroxyurea in the treatment of HIV infection.
Expert opinion on drug safety 2004;3(4):279-88.
2004: Andrea Foli; Renato Maserati; Gabriele Barasolo; Francesco Castelli; Lina Tomasoni; Marco Migliorino; Franco Maggiolo; Angelo Pan; Stefania Paolucci; Luigia Scudeller; Carmine Tinelli; Richard D'Aquila; Julianna Lisziewicz; Franco Lori
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Antiviral therapy 2004;9(1):123-32.
2003: Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
Drug safety : an international journal of medical toxicology and drug experience 2003;26(9):605-24.
2002: Franco Lori; Andrea Foli; Julianna Lisziewicz
Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects.
The Journal of antimicrobial chemotherapy 2002;50(2):155-60.
2002: Franco Lori; Andrea Foli; Renato Maserati; Elena Seminari; Jianqing Xu; Lucia Whitman; Elisabetta Ravot; Francesco Alberici; Lucia Lopalco; Julianna Lisziewicz
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.
HIV clinical trials 2002;3(2):115-24.
2002: Giampiero Piccinini; Andrea Foli; Giuditta Comolli; Julianna Lisziewicz; Franco Lori
Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.
Journal of virology 2002;76(5):2274-8.
2002: Andrea Foli; Elena Seminari; Elisabetta Ravot; Julianna Lisziewicz; Franco Lori
Role of hydroxyurea during structured treatment interruptions.
Journal of biological regulators and homeostatic agents 2002;16(1):64-8.
2001: Andrea Foli; F Benvenuto; Giampiero Piccinini; A Bareggi; A Cossarizza; Julianna Lisziewicz; Franco Lori
Direct analysis of mitochondrial toxicity of antiretroviral drugs.
AIDS (London, England) 2001;15(13):1687-94.
2000: Franco Lori; R Maserati; Andrea Foli; Elena Seminari; J Timpone; Julianna Lisziewicz
Structured treatment interruptions to control HIV-1 infection.
Lancet 2000;355(9200):287-8.
1999: Franco Lori; E Rosenberg; Judy Lieberman; Andrea Foli; Renato Maserati; Elena Seminari; F Alberici; B Walker; Julianna Lisziewicz
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
AIDS research and human retroviruses 1999;15(15):1333-8.
1999: Elena Seminari; Julianna Lisziewicz; Carmine Tinelli; Andrea Foli; Franco Lori; Renato Maserati
Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
International journal of clinical pharmacology and therapeutics 1999;37(10):514-8.
1998: Andrea Foli; Renato Maserati; Lorenzo Minoli; M A Wainberg; Robert C Gallo; Julianna Lisziewicz; Franco Lori
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
AIDS (London, England) 1998;12(9):1113-4.
1997: Franco Lori; Andrei Malykh; Andrea Foli; Renato Maserati; A De Antoni; Lorenzo Minoli; D Padrini; A Degli Antoni; E Barchi; Heiko Jessen; M A Wainberg; Robert C Gallo; Julianna Lisziewicz
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
AIDS research and human retroviruses 1997;13(16):1403-9.
1997: A De Antoni; Andrea Foli; Julianna Lisziewicz; Franco Lori
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
The Journal of infectious diseases 1997;176(4):899-903.
1997: Franco Lori; Heiko Jessen; Andrea Foli; Julianna Lisziewicz; P S Matteo
Long-term suppression of HIV-1 by hydroxyurea and didanosine.
JAMA : the journal of the American Medical Association 1997;277(18):1437-8.
1997: Andrea Foli; Franco Lori; Renato Maserati; Carmine Tinelli; Lorenzo Minoli; Julianna Lisziewicz
Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Antiviral therapy 1997;2(1):31-8.